Module 4
Monitoring, Tracking, and Adjusting
Learning Objectives
Compare the four available methods for measuring ketosis and articulate the clinical strengths and limitations of each
Apply blood beta-hydroxybutyrate (BHB) as the gold-standard measure of nutritional ketosis and correctly interpret values across the physiological spectrum.
Counsel patients on appropriate frequency of ketone monitoring based on phase of intervention and clinical context.
Interpret key biomarkers in the context of ketogenic nutrition
Monitor for signs of inadequate adaptation or nutritional deficiency
Make data-driven adjustments based on clinical and client-reported outcomes.
Determine when physician consultation is required.
In this module
SECTION 4.1
4.1 Ketone Measurement: Methods, Interpretation, and Frequency
Why Measure Ketones?
A central advantage of the well -formulated ketogenic diet (WFKD) compared with most dietary interventions is the availability of an objective, real -time biomarker of adherence: circulating ketone bodies. When dietary carbohydrate remains below approximately 50 g/day in the context of adequate protein and energy intake, hepatic ketogenesis is upregulated and blood ketone levels rise into the nutritional ketosis range. Conversely, even modest dietary lapses — or excess protein intake — promptly suppress ketogenesis, causing BHB to fall below the 0.5 mM threshold. This sensitivity makes ketone measurement a uniquely useful clinical and behaviora l tool (Volek 2012). Specific reasons to measure ketones include:
- Confirming dietary adherence and metabolic state in new adopters.
- Spot checks for dietary intake to avoid protein or carbohydrate creep
- Support dietary adjustments needed for stalls or struggles with glucose / body weight
- Educating patients on the dose -response relationship between carbohydrate intake and ketosis.
- Identifying hidden carbohydrate sources responsible for suppressing ketosis.
- Informing therapeutic decisions in clinical populations (e.g., epilepsy, T2D, SGLT2i use).
- Providing motivational feedback to support behavioral consistency.
- Differentiating nutritional ketosis from diabetic ketoacidosis (DKA) in high -risk patients.
Brief Biochemistry: Which Ketones Are We Measuring?
The liver produces three ketone bodies from fatty acid beta -oxidation:
- Beta-hydroxybutyrate (BHB): The predominant circulating ketone, comprising 70 –80% of total blood ketones at steady state. BHB is the molecule measured by blood ketone meters.
- Acetoacetate (AcAc ): The second major ketone body (20 –25%), measured by urine dipstick. During early adaptation, AcAc is actively secreted into urine, but its fractional excretion declines with keto -adaptation.
- Acetone: A minor volatile ketone (2 –5%) produced by the spontaneous non -enzymatic decarboxylation of AcAc. Because it is volatile, acetone is exhaled in proportion to blood ketone levels — the basis of breath ketone monitoring.
Clinical significance:
Because the three ketone bodies are biochemically and kinetically distinct, each measurement method captures a different molecule at a different compartment, with different time lags and susceptibility to adaptation-related changes. This is fundamental to understanding why the methods diverge in accuracy over time.
Ketone Measurement Methods: Comprehensive Comparison
Accuracy Ranking Summary
Blood BHB ≥ Continuous Monitor (interstitial BHB) > Breath Acetone ≫ Urine Acetoacetate
Why urine strips fail the keto-adapted patient:
: During the first 1-2 weeks of a WFKD, urine ketone strips reliably detect acetoacetate because the renal tubules have not yet adapted to conserve ketones. However, as keto-adaptation proceeds, the kidneys progressively reabsorb the majority of filtered ketones — a conservation mechanism analogous to glucose reabsorption. Within 2-4 weeks, urine ketone excretion drops markedly, and strips routinely read trace or negative even in individuals with blood BHB well within nutritional ketosis (0.5–3.0 mM). This urine ketone decline coincides precisely with the normalization of serum uric acid (which competes with ketones for renal tubular excretion during early adaptation).Consequently, practitioners who rely on urine ketone strips may incorrectly conclude that keto-adapted individuals are no longer in nutritional ketosis, whereas blood β-hydroxybutyrate testing provides a more direct assessment of ketosis status (Volek & Phinney 2011).
SECTION 4.2
4.2 Blood BHB: The Preferred Clinical Method
Blood BHB testing via finger -prick meter is the clinical and research gold standard for ketone monitoring. It directly measures the primary circulating ketone body, is not affected by adaptation -related changes in renal handling or respiratory physiology and is required in all situations where clinical accuracy is essential (including published clinical research) . The following sections are based on blood BHB interpretation.
Meter Selection and Setup
Two dedicated blood ketone meters are widely used in clinical and research practice:
- Keto-Mojo GK+ / Triple Meter: Measures blood BHB and glucose from the same finger -prick sample. Dual -function is advantageous for patients requiring concurrent glucose monitoring. Good clinical accuracy .
- Precision Xtra (Abbott): One of the most studied blood ketone meters in peer -reviewed literature. High accuracy; requires separate glucose strips. Practitioners should counsel patients on the following setup points:
- Use the device’s BHB strips specifically — glucose strips do not measure ketones.
- Wash hands with warm water to avoid contamination and dry thoroughly.
- Warm the hands if they are cold.
- Gently massage from the base of the finger toward the tip to encourage blood flow.
- Sample from the side of a fingertip using a 28 –30 gauge lancet; adequate blood drop size is essential for accurate reading.
- Store strips at room temperature; do not use expired strips. *Additional instructions specific to the device, including calibration, can be found in the instruction manual.
Blood BHB Ranges: Physiological Spectrum
Interpreting blood BHB requires understanding the full physiological continuum from baseline fasting to DKA:
Understanding Declining BHB Over Time: Adaptation, Not Failure
One of the more common issues that practitioners must proactively address is a progressive decline in blood BHB levels over the first several months of a WFKD. Patients frequently become alarmed that their ketone levels have dropped from early peaks of 2.0 –3.0 mM to sustained levels of 0.7 –1.2 mM, interpreting this “ falling out of ketosis” as metabolic fatigue or dietary intolerance.
This decline can be a hallmark of successful keto -adaptation , and the mechanism – while yet to be fully defined – involves a part of keto-adaptation in which the body is increasingly able to use acetone to make glucose (Reichard 19 79). This, combined with increased uptake of BHB out of circulation and into cells can lead to reduced blood levels despite the same rate of production by the liver. Since it is the BHB in muscle , brain , and other organs that produces its metabolic benefits, this modest reduction in blood levels appears to have no negative effect on the keto -adapted state.
However , the other factor contributing to declining blood ketones over the first months of a WFKD is managing the necessary natural progression of eating fat to satiety from the initia l few months to long term maintenance after 6 -12 months. In the prior graph showing an example of how macronutrient amounts - and particularly daily fat intake – need to change over this time period , fat intake needs to increase from 820 kcal/day to 1400 kcal/day. That’s an increase of 580 kcal or about 65 grams of additional fat per day.
For people who have been repeatedly advised to eat a low fat diet or least to some degree, fear “too much” fat, for the last 45 years, this is hard to do. Learning to s hop different isles and negotiating entrees (have you ever ordered a 30 gram side of butter with your small steak or chicken breast?) in restaurants takes coaching and practice. In this setting, it is tempting to just increase one’s protein intake (the 12 oz steak rather than the 6 oz option ) or add a bit more carbohydrate to satisfy the needed calories for maintenance. Early in a WFKD, skeletal muscle readily oxidizes both BHB and acetoacetate as it transitions from glucose to fat -based fuel.
- As keto -adaptation proceeds over weeks to months, muscle cells develop a metabolic preference for direct fatty acid oxidation, and begin returning acetoacetate (converted back to BHB) to the circulation rather than oxidizing it directly.
- This means BHB accumulates less in muscle, and circulating levels reflect primarily brain utilization, which is itself more efficient.
- The net result: peripheral ketone extraction increases, circulating BHB levels drop to a new steady state, but total ketone body turnover and brain fuel supply are maintained or improved.
Clinical Pearl: Declining BHB
Counsel patients proactively: 'Your ketones may be lower at 3 months than they were at 3 weeks despite maintaining your same daily protein and carbohydrate targets . This can reflect your body becoming more metabolically efficient — your tissues are extracting ketones more effectively, so less a re present in your blood. A fasting BHB of 0.7 mM at month -3 may still represent fully adapted nutritional ketosis. But also be wa ry of macronutrient creep at any point and especially as one approache s weight stability if ketones are falling.
SECTION 4.3
4.3 Frequency of Ketone Monitoring: Clinical Guidance
Monitoring frequency should be individualized based on phase of intervention, clinical risk, and patient goals. The following framework provides evidence -informed guidance:
Clinical Pearl: Tracking Frequency
Daily BHB logging during the first 4 weeks is arguably the highest -yield monitoring activity in early WFKD implementation. It teaches patients to stay within their personal carbohydrate tolerance , identifies 'keto killers' in their diet, and transitions seamlessly into the education role of the practitioner. After the first 1 -2 months, logging frequency can be reduced as patterns become internalized. When trying something new, troubleshooting, or a spot check, ketone checks can be a helpful tool.
SECTION 4.4
4.4 Common Causes of Low Ketones
Common Hidden Carbohydrate Sources to Flag
Patients frequently underestimate carbohydrate intake from the following sources. If achieving or sustaining nutritional ketosis is problematic, r eview these at the 2 –4 week follow -up visit:
- Condiments and sauces: ketchup, teriyaki, hoisin and oyster sauce , barbecue sauce, sweet chili sauce, many salad dressings.
- Sugar -free products: those sweetened with maltitol, sorbitol, or other polyols that have a modest but significant glycemic impact despite the ‘sugar -free’ label.
- Restaurant preparation: foods may be marinated, breaded, thickened with flour, or finished with sweet ened or fruit -based glazes.
- Nuts: cashews, pistachios, and mixed nuts have meaningfully higher carbohydrate content than macadamias, pecans, and walnuts. Even ‘allowed’ nuts contribute to carb totals in volume.
- Dairy products: milk and some yogurts have significant lactose content (half of which is glucose) . True c heese (not ‘cheese products’) , heavy cream, and butter are very low -carb; Greek yogurt (plain) is moderate.
- Vegetables: most above -ground vegetables are appropriate ; starchy root vegetables (sweet potato, potato, beets, carrots in large quantities), corn , winter squash, fresh tomato, kidney beans , and peas must be limited.
SECTION 4.5
4.5 Body Composition and Comprehensive Progress Monitoring
Beyond the Scale
Scale weight is a noisy, incomplete metric of metabolic progress. Acute weight fluctuations of 1 –3 pounds are common on a daily basis due to hydration status, glycogen flux, gastrointestinal contents, and sodium balance — none of which reflects true fat ma ss change. A successful continuous care model captured treatment response s and provided routine feedback to patients across a comprehensive array of outcome metrics ; including A1C, fasting insulin, and medication use, in addition to weight (Hallberg 2018). Practitioners must equip patients with a fuller set of progress markers while de -emphasizing daily weight measurements .
Note:
NSAID medications, both OTC and prescription versions, can cause the kidneys to retain salt and water. This can result in prompt weight gains of 2 -6 lbs, particularly in patients who are metabolically impaired (diabetes, hypertension, heart disease) and the aged. This effect resolves promptly upon cessation of the drug (Whelton 1991) .
Defining and Troubleshooting Weight Loss Stalls
A true weight loss plateau on a WFKD is defined as no change in body weight or waist circumference over 3 –4 consecutive weeks in a patient who has not ye t achieved a healthy weight reduction threshold – e.g. 10 -15% or metabolic improvement goal. The breadth and depth of metabolic adaptations that occur with significant weight loss are highly individualized . The data in the scientific literature are far from conclusive when it comes to impact of weight loss – with and without exercise – on total and resting energy expenditure. Whether a WFKD differently impacts total and resting energy expenditure as compared to other nutritional weight loss interventions is still unclear and requires more tightly -controlled experiments before strong conclusions can be made. Ultimately, the impa ct of weight loss on energy expenditure should be considered as part of the overall picture, with the understanding that responses are highly i ndividualized.
Weight Loss Stall Troubleshooting Checklist
Systematic Clinical Troubleshooting Checklist
Work through each factor systematically when a patient’s weight loss stalls.
SECTION 4.6
4.6 Interpreting Laboratory Biomarkers on a WFKD
Common Misinterpretations and Clinical Guidance
Several standard laboratory findings are routinely misinterpreted in the context of a WFKD. The most clinically significant of these — and the most likely to provoke conflict between the nutrition practitioner and prescribing physician — is total LDL chole sterol. Practitioners must be prepared to contextualize these findings clearly and advocate for appropriate additional testing where indicated.
When to Consult the Prescribing Physician
Practitioners must recognize situations requiring urgent or non -urgent physician referral:
Disclaimer
This content is provided by The Ketogenic Foundation for educational and informational purposes only and does not constitute medical, nutritional, dietetic, or other professional advice. It is not intended to diagnose, treat, cure, or prevent a ny disease. This content does not create any professional relationship or duty of care between The Ketogenic Foundation and any reader, nor does it create or replace any practitioner –client or provider –patient relationship. Nothing in this content expands any reader's scope of practice; each professional remains solely responsible for acting within the limits of their own license, certification, credential, and applicable federal, state, and local law, and for referring to or coordinating with an appropriat ely licensed professional where required. Individualized clinical or nutritional decisions should be made in consultation with a qualified, appropriately licensed healthcare professional. Reliance on this content is at the user's own discretion and risk.
KNOWLEDGE ASSESSMENT
Module 4 — Knowledge Assessment
Answer the following questions to assess your understanding of Module 4 content.
QUESTION 1
A client's fasting blood BHB has declined from 2.0 –2.5 mM during her first month to 0.8 –1.0 mM at month 3. She reports her urine ketone strips now read negative. She is alarmed that she has 'fallen out of ketosis.' What is the most appropriate clinical res ponse?
A. Reassure her that the decline in both blood BHB and urine ketones are consistent with successful keto-adaptation: peripheral tissues extract ketones more efficiently, the kidneys reabsorb a greater fraction of filtered ketones, and blood BHB of 0.8 –1.0 mM confirms she remains in nutritional ketosis.
B. Instruct her to reduce protein intake further to increase ketone production.
C. Recommend exogenous ketone supplementation to restore earlier levels.
D. Discontinue the dietary intervention as ketosis can no longer be confirmed by urine testing.
Reveal answer
QUESTION 2
A practitioner wants to monitor a new patient’s ketone levels. The patient is a 44 -year-old woman recently diagnosed with T2D on metformin only (no insulin or sulfonylureas). She a finger -stick glucometer that can also measure blood ketones but has heard that urine strips are cheaper. What is the most appropriate guidance on measurement method and frequency?
A. Urine strips are appropriate because she is not on insulin; use them daily.
B. Breath acetone meter is equivalent to blood testing and preferable for this patient.
C. No monitoring is needed because she is not on glucose -lowering medications that create hypoglycemia risk.
D. Blood BHB testing is preferred because it is accurate across all stages of adaptation; urine strips may be used in the first 1 –2 weeks only for initial confirmation. Recommend fasting blood BHB daily for the first 4 weeks, then 3 –4×/week during stabiliz ation.
Reveal answer
QUESTION 3
A 61-year-old man with T2D on insulin glargine (18 units/day) begins a WFKD. After 2 weeks, his fasting glucose has normalized to 95 –110 mg/dL and he has experienced three documented hypoglycemic episodes (blood glucose <65 mg/dL). Fasting BHB is 1.4 mM. W hat is the most appropriate response?
A. Instruct him to increase carbohydrate intake if hypoglycemi c episodes continue .
B. Immediately contact his prescribing physician to discuss insulin dose reduction. Fasting glucose normalization and recurrent hypoglycemia in the context of confirmed ketosis (BHB 1.4 mM) indicate that the WFKD has dramatically reduced his insulin requir ement. Insulin dose reduction is urgent.
C. Have him discontinue the WFKD pending evaluation.
D. Instruct him to skip his insulin dose on days he exercises.
Reveal answer
QUESTION 4
An obese client doing well on a WFKD has a lipid panel done at 3 months show ing: Total cholesterol 240 mg/dL (up from 205), LDL -C 155 mg/dL (up from 130), HDL -C 72 mg/dL (up from 48), triglycerides 75 mg/dL (down from 210). Her primary care physician wants to initiate a statin. What is the most clinically relevant information to pres ent?
A. LDL -C elevation is definitive evidence of increased cardiovascular risk; statin therapy is appropriate.
B. The Trig/HDL ratio has improved dramatically (1.04 vs. prior 4.38), which is the cardiometabolic signature of improved insulin sensitivity and a shift toward the large -buoyant LDL phenotype. The s tatin Rx decision should be made between the patient and her primary care doctor, but in this case an NMR lipid particle characterization would be helpful.
C. The diet should be discontinued immediately due to LDL -C elevation.
D. All cholesterol elevations on WFKD are benign and no workup is needed.
Reveal answer
QUESTION 5
A patient on a SGLT2 inhibitor (empagliflozin) for T2D asks whether she needs to monitor ketones when starting a WFKD, noting that ‘her blood sugars have been fine’ and she doesn’t want to ‘bother with finger pricks’. What is the most appropriate response?
A. Agree that monitoring is not needed if her blood sugars are controlled.
B. Recommend breath ketone monitoring as a non -invasive alternative.
C. Explain that SGLT2 inhibitors independently promote ketogenesis, creating a small but real risk of euglycemic DKA (blood glucose normal but BHB dangerously elevated). Daily blood BHB monitoring is required for at least the first 4 –8 weeks on combined SG LT2i + WFKD, and any BHB trend above 3.0 mM warrants immediate physician notification (Blau, 2018). Urine ketone strips are NOT adequate for this population.
D. Advise her to stop the SGLT2i before starting a WFKD.
Reveal answer
References
Athinarayanan SJ, Roberts CG, Phinney SD, Weimbs T, Friedman AN, Volek JS. Effects of a continuous remote care intervention including nutritional ketosis on kidney function and inflammation in adults with type 2 diabetes: a post -hoc latent class trajectory analysis. Frontiers in Nutrition. 2025 Jun 6;12:1609737.
Blau JE, Tella SH, Taylor S, et al. Ketoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data. Diabetes Metab Res Rev. 2018;33(8).
Cahill GF Jr. Starvation in man. N Engl J Med. 1970;282(12):668 –675.
Cahill Jr GF. President’s address. Starvation. Transactions of the American Clinical and Climatological Association. 1983;94:1.
Drenick EJ, Alvarez LC, Tamasi GC, Brickman AS. Resistance to symptomatic insulin reactions after fasting. The Journal of clinical investigation. 1972 Oct 1;51(10):2757 -62.
Fante C, et al. The role of β -hydroxybutyrate testing in ketogenic metabolic therapies. Front Nutr. 2025;1(12).
Fried PI, McClean PA, Phillipson EA, Zamel N, Murray FT, Marliss EB. Effect of ketosis on respiratory sensitivity to carbon dioxide in obesity. New England Journal of Medicine. 1976 May 13;294(20):1081 -6.
Hallberg SJ, McKenzie AL, Williams PT, et al. Effectiveness and safety of a novel care model for the management of type 2 diabetes at 1 year. Diabetes Therapy. 2018;9(2):583 –612.
Hyde PN, Sapper TN, Crabtree CD, LaFountain RA, Bowling ML, Buga A, Fell B, McSwiney FT, Dickerson RM, Miller VJ, Scandling D. Dietary carbohydrate restriction improves metabolic syndrome independent of weight loss. JCI insight. 2019 Jun 20;4(12):e128308.
Lyman KS, Athinarayanan SJ, McKenzie AL, Pearson CL, Adams RN, Hallberg SJ, McCarter JP, Volek
JS, Phinney SD, Andrawis JP. Continuous care intervention with carbohydrate restriction improves physical function of the knees among patients with type 2 diabet es: a non -randomized study. BMC
Musculoskeletal Disorders. 2022 Mar 29;23(1):297.
McKenzie A, Athinarayanan S, Adams R, Hallberg S, Volek J, Phinney SD. Predictors of normalization of fasting glucose in patients with prediabetes using remote continuous care emphasizing low carbohydrate intake. Journal of the Endocrine Society. 2021 May 3;5(Suppl 1):A323.
Phinney SD, Tang AB, Waggoner CR, Tezanos -Pinto RG, Davis PA. The transient hypercholesterolemia of major weight loss. The American journal of clinical nutrition. 1991 Jun 1;53(6):1404 -10
Reichard GA Jr, Skutches CL, Hoeldtke RD, Owen OE. Acetone metabolism in humans during diabetic ketoacidosis. Diabetes. 1986;35(6):668 –674.
Reichard GA, Haff AC, Skutches CL, Paul P, Holroyde CP, Owen OE. Plasma acetone metabolism in the fasting human. The Journal of clinical investigation. 1979 Apr 1;63(4):619 -26.
Retterstol K, et al. LDL particle size and triglyceride/HDL ratio in assessing cardiovascular risk. Eur J Prev Cardiol. 2022.
Whelton A, Hamilton CW. Nonsteroidal anti ‐inflammatory drugs: effects on kidney function. The Journal of Clinical Pharmacology. 1991 Jul;31(7):588 -98.
Volek J, Phinney SD. The art and science of low carbohydrate performance: A revolutionary program to extend your physical and mental performance envelope. Beyond Obesity; 2012.
Volek JS, Phinney SD. The Art and Science of Low Carbohydrate Living. Beyond Obesity LLC; 2011.
Volek JS, Phinney SD, Forsythe CE, et al. Carbohydrate restriction has a more favorable impact on the metabolic syndrome than a low fat diet. Lipids. 2009;44(4):297 –309.
Volek JS, Kraemer WJ, Bush JA, et al. Testosterone and cortisol in relationship to dietary nutrients and resistance exercise. J Appl Physiol. 1997;82:49 –54. [Note: For lipid subfractions on LCD, see Volek et al., 2015, PMID: 25833964.]
Contact Us
952 School Street, Suite 212
Napa, CA 94559